It’s always an event when we spend time together

Dr. Jack Scannell’s career spans neuroscience, drug discovery, consulting, and biopharma investment. His current work focuses on the ability of disease models to predict clinical outcomes in patients—a passion that developed from his long-term in the technological and economic history of biomedical innovation. He coined the term “Eroom’s Law,” or the exponential decline in biopharmaceutical R&D productivity between 1950 and 2010, to contrast with the more familiar Moore’s Law, which describes the exponential increase in computing power over a similar period. “Eroom” is “Moore” backwards. He is also known for his articles explaining the realpolitik of drug pricing. Jack was Co-Head of European Pharmaceuticals and Biotech at UBS Investment Bank as well as Head of European Healthcare at Sanford Bernstein. He led Discovery Biology at E-Therapeutics PLC, an Oxford-based biotech firm. He started his commercial career at the Boston Consulting Group. Before that, he was an academic neuroscientist. He has a D.Phil. in Physiology (Neuroscience) from Oxford and a bachelor’s degree in Medical Sciences from Cambridge.

Lorna Ewart is Executive Vice President of Science at Emulate. She has over 20 years of experience in the pharmaceutical industry, spanning Bioscience and Drug Safety. In her role at Emulate, Ewart provides oversight for the company’s scientific vision and advancement with academic, industry, and regulatory partners.

Prior to joining Emulate, Ewart established the Microphysiological Systems Centre of Excellence within AstraZeneca’s R&D Biopharmaceuticals Unit in Cambridge, UK and was the therapy area lead toxicologist for Respiratory and Inflammation in AstraZeneca’s Gothenburg R&D site in Sweden. Following her Ph.D., she joined the Respiratory and Inflammation research area within AstraZeneca, optimizing efficacy in small molecules before moving into preclinical Drug Safety, where she led a Safety Pharmacology team delivering GLP data across multiple therapeutic areas.

Ewart is a classically trained pharmacologist and obtained her honors degree at the University of Aberdeen and her Ph.D. at the William Harvey Research Institute in London. She has authored over publications specific to organ-chip technology and is a fellow of the Royal Society of Biology and British Pharmacological Society.

Daniel Levner is the Chief Technology Officer at Emulate. A serial deep-tech entrepreneur, Levner co-founded Emulate and brings to it extensive experience in biological and engineering technology development and commercialization. Levner joined the Emulate founding team during his role as a Senior Staff Scientist with the Wyss Institute for Biologically Inspired Engineering at Harvard University. There, he led the advanced engineering team responsible for developing the Emulate Organ-Chips platform and played a key leadership role formulating innovative approaches for bridging biologists, engineers, and business stakeholders.

Prior to directing the Organs-on-Chips program, Levner worked with world-renowned Harvard geneticist Prof. George M. Church in programs related to medical diagnostics, DNA/RNA sequencing, and multiplexed biological sample analysis techniques. As an entrepreneur, Levner co-founded a medical diagnostics startup company and, earlier in his career, an optical telecommunications startup company.

Levner received his Ph.D. in electrical engineering from Stanford University as well as an M.S. in aeronautics and astronautics, also from Stanford. He has authored numerous publications and more than 70 issued and pending US patents.